04.01.03
Roche, Basel, Switzerland, and DSM, Delft, The Netherlands, have completed the agreement for DSM to acquire Roche’s vitamins, carotenoids and fine chemicals business. Although the transaction is subject to approval by anti-trust authorities, both Roche and DSM expect that the closing will take place in the first half of 2003. DSM will reportedly pay a transaction price of e1.95 billion to Roche, e1.85 billion in cash plus e2.24 million DSM shares with a value of approximately e100 million. The difference to the transaction value indicated in September 2002 of e2.25 billion is a result of the continued slow-down of the world’s economies and the weakening of the value of the U.S. dollar versus the Swiss Franc, which both had a negative impact on the vitamin business performance compared to earlier forecasts.
In other news, Roche recently opened an EGCG plant in Shanghai, China. It will begin with an annual output of more than 40 tons. With the new investment, Roche becomes the world’s first industrial manufacturer of pure EGCG, which it will market under the trade name TEAVIGO. TEAVIGO can be widely used in beverages, solid foods, pharmaceutical products and dietary supplements without impairing the color or taste profile of the final product.
In other news, Roche recently opened an EGCG plant in Shanghai, China. It will begin with an annual output of more than 40 tons. With the new investment, Roche becomes the world’s first industrial manufacturer of pure EGCG, which it will market under the trade name TEAVIGO. TEAVIGO can be widely used in beverages, solid foods, pharmaceutical products and dietary supplements without impairing the color or taste profile of the final product.